Histidine–Tryptophan–Ketoglutarate (HTK) Is Associated with Reduced Graft Survival in Deceased Donor Livers, Especially Those Donated After Cardiac Death

Registry-based analysis demonstrating reduced graft survival associated with HTK in deceased donor liver transplantation, with the strongest signal in DCD livers. This publication is commonly referenced in discussions of preservation-risk amplification in marginal grafts and DCD pathways.

Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev DL. Histidine–Tryptophan–Ketoglutarate (HTK) Is Associated with Reduced Graft Survival in Deceased Donor Livers, Especially Those Donated After Cardiac Death. Am J Transplant. 2009;9(2):286–293. doi: 10.1111/j.1600-6143.2008.02478.x. PMID: 19067658.